- Progyny recently reported that its P/E multiple moved from 75.6 in mid 2023 to 28.4 at the latest close, as profitability metrics such as net income of US$78.6 million over the latest twelve months and a 180 basis points gross margin expansion in the second quarter combined with share buybacks.
- The shift in Progyny's valuation multiple, alongside higher net income and margin expansion, points to the market focusing more on earnings power and capital return than on headline growth expectations.
- Next, the focus moves to how Progyny's improved profitability and lower P/E multiple may reshape the broader investment narrative around the business.
Compare Progyny's reset P/E and improving profitability with other potential opportunities and scan our hand picked 29 high quality undervalued stocks that the market may be pricing differently today.
Progyny Investment Narrative Recap
To own Progyny, you need to be comfortable that employer demand for fertility and broader women's health benefits remains resilient and that the platform can keep turning that demand into earnings. The recent reset in the P/E multiple, together with stronger profitability, shifts attention to execution on margins, cash generation and how consistently clients adopt additional services.
In the near term, the key swing factor is whether utilization and new client wins support the current revenue base while Progyny scales newer offerings such as menopause and postpartum support. The biggest risk is employers pulling back on premium benefits as they manage costs. That would test both volume growth and the ability to widen margins.
The upcoming September quarter results and conference call on 4 November 2026 occur alongside this valuation reset. That update represents the next checkpoint for how Progyny converts its product range and health plan partnerships into earnings and cash flow at the new P/E level.
Investors will likely watch several items on that call. These include any commentary on employer benefit budgets, trends in assisted reproductive technology cycles, uptake of newer women's health products and how share repurchases fit alongside growth spending, given that management has already reduced the share count and kept the balance sheet free of debt.
Progyny Forecasts And What Needs To Go Right
Progyny now sits at a point where the story is less about headline growth and more about how the earnings profile evolves relative to analyst assumptions. The current analyst framework sketches out what needs to happen on revenue, profitability and valuation multiples for the recent reset in the P/E to make sense over the next few years.
For the top line, analysts are working with a forecast that revenue grows by 8.4% each year over the next three years. That is not a hyper growth assumption. It implies a steady expansion in employer programs and member usage rather than a surge, which matters for anyone comparing Progyny with higher growth health benefits peers or more mature healthcare services businesses.
Profitability is where the expectations sharpen. Earnings today are put at US$78.6 million, and the consensus view looks for that to reach US$149.5 million by 2029. That is roughly a 90% increase in profit, supported by an assumed uptick in margins from 6.0% to 9.0% over three years as the benefits platform scales and share repurchases lift earnings per share.
Underlying those estimates is a wide spread in individual forecasts. The most optimistic analysts see earnings at US$175.7 million by 2029, while the most cautious pencil in US$103.5 million. That range shows how much uncertainty still sits around the pace of employer adoption, utilization trends across fertility and broader women's health benefits, and the timing of any margin gains.
Valuation embeds its own checklist. For readers to align with the current analyst price target, the consensus model assumes that by 2029 Progyny delivers about US$1.7b in revenue and US$149.5 million in earnings, and that the shares then trade on a 17.5x P/E multiple. That would be lower than both the current P/E of 24.6x attached to Progyny and the 24.3x analysts cite for the wider US Healthcare group.
Analysts also build in roughly 7.0% yearly declines in the share count over the next three years, reflecting ongoing buybacks. That shrinking denominator can lift earnings per share even if net income grows more gradually, so readers need to separate what comes from genuine operating progress from what comes from capital returns when weighing those EPS numbers.
Progyny's projections point to US$1.7b in revenue and US$149.5 million in earnings by 2029. That path assumes 8.4% yearly revenue growth and roughly a US$70.9 million earnings increase from current earnings of US$78.6 million.
Uncover why Progyny's fair value indicates an 18% potential upside to its current price that could narrow quickly.
Exploring Other Perspectives
One alternate view leans hard into Progyny's broader women's health push as a potential upside catalyst. Those bullish analysts were modelling roughly US$1.8b of revenue and US$175.5 million in earnings by 2029, compared with the baseline US$1.7b and US$149.5 million before this P/E reset and profitability news, so expect some narratives to shift.
Explore 3 other Progyny fair value estimates, including one that suggests as much as 158% upside from the current price!
The Verdict Is Yours
Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.
- A great starting point for your Progyny research is our analysis highlighting 3 key rewards that could impact your investment decision.
- See our latest analysis for Progyny. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Progyny's overall financial health at a glance.
Looking For More Investment Ideas Beyond Progyny?
Once you have a handle on Progyny, it can help to widen the lens and compare its profile with other listed companies that share some of the traits you care about most. The Simply Wall St Screener lets you do exactly that by filtering for balance sheets, income quality and capital return policies that match your preferences.
- If capital preservation and steadier return profiles matter to you, consider starting with a basket of companies screened as 30 resilient stocks with low risk scores that may better align with a cautious approach.
- If you want businesses that combine sturdy financial footing with earning power, scan the list of solid balance sheet and fundamentals (26 results) to see which tickers fit a more quality focused brief.
- If you are hunting for opportunities that may be earlier in the market spotlight, review the 20 high quality undiscovered gems and see which stories you want to research next.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com